Skip to search formSkip to main contentSkip to account menu
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
TLDR
The available data indicate no significant difference in efficacy between dabigatran 150 mg and apixaban for the prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation.
View on PubMed
Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis
TLDR
In this meta-analysis of eight observational studies, the use of progestin-only contraception was not associated with an increased risk of venous thromboembolism compared with non-users of hormonal contraception and the potential association between injectable progestins and thrombosis requires further study.
View on Publisher
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
TLDR
It is found mutations are selected differentially based on exposures, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2).
View on PubMed
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study)
TLDR
Enoxaparin demonstrated a clear trend towards reducing the rate of VTE in patients with elevated levels of TFMP, with an overall rate ofVTE similar in magnitude to the lower TFMP group.
View on Wiley
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
TLDR
Overall, apixaban appears to be associated with a lower risk of bleeding than the other TSOA’s, and a dedicated randomized trial directly comparing the new agents would be required to confirm these results.
View on Springer
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study
TLDR
In this cohort of 200 patients with active cancer and CAT the rates of new or recurrent VTE and major bleeding were comparable to the cancer subgroup analysis from the EINSTEIN studies, and safety and efficacy is preserved, compared with past-published experience with LMWH.
View on Springer
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
TLDR
In this large cohort of APL patients, high white blood cell count emerged as an independent predictor of early HD.
View on PubMed
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
TLDR
Romiplostim is effective in correcting CIT, and maintenance allows for resumption of chemotherapy without recurrence of CIT in most patients.
View PDF
Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review
TLDR
There is a trend for increased live births when using LWMH for the prevention of recurrent pregnancy loss, and there is insufficient evidence to support the routine use of L WMH to improve pregnancy outcomes in women with a history of pregnancy loss.
View on Wiley
New Avenues for Anticoagulation in Atrial Fibrillation
TLDR
E efficacy and safety appear to be noninferior, and in some instances superior, to warfarin, however, the new drugs have their downsides, and switching from warfar in is not recommended for all patients.
View on Wiley
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License